Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Genetic Disorders Partnering 2012-2018: Deal Trends, Players and Financials -

Research and Markets
Posted on: 23 Mar 18

The "Global Genetic disorders Partnering 2012-2018: Deal trends, players and financials" report has been added to's offering.

Global Genetic Disorders Partnering 2012 to 2018 provides the full collection of Genetic Disorders disease deals signed between the world's pharmaceutical and biotechnology companies since 2012.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Genetic Disorders disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genetic Disorders deals.

The report presents financial deal terms values for Genetic Disorders deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

In addition, a comprehensive appendix is provided with each report of all Genetic Disorders partnering deals signed and announced since 2012. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Genetic Disorders dealmaking

2.1. Introduction

2.2. Genetic Disorders partnering over the years

2.3. Genetic Disorders partnering by deal type

2.4. Genetic Disorders partnering by industry sector

2.5. Genetic Disorders partnering by stage of development

2.6. Genetic Disorders partnering by technology type

2.7. Genetic Disorders partnering by therapeutic indication

Chapter 3 -Financial deal terms for Genetic Disorders partnering

3.1. Introduction

3.2. Disclosed financials terms for Genetic Disorders partnering

3.3. Genetic Disorders partnering headline values

3.4. Genetic Disorders deal upfront payments

3.5. Genetic Disorders deal milestone payments

3.6. Genetic Disorders royalty rates

Chapter 4 - Leading Genetic Disorders deals and dealmakers

4.1. Introduction

4.2. Most active in Genetic Disorders partnering

4.3. List of most active dealmakers in Genetic Disorders

4.4. Top Genetic Disorders deals by value

Chapter 5 - Genetic Disorders contract document directory

5.1. Introduction

5.2. Genetic Disorders partnering deals where contract document available

Chapter 6 - Genetic Disorders dealmaking by therapeutic target

6.1. Introduction

6.2. Deals by Genetic Disorders therapeutic target

For more information about this report visit

View source version on

Business Wire

Last updated on: 23/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.